Thus, lower drug uptake or high drug extrusion may create a favorable environment for CML cells acquiring other resistance mechanisms, such as BCR-ABL1 mutations [23,111]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.